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ABSTRACT
Background: Familial adenomatous polyposis (FAP) is a
well-described inherited syndrome, which is responsible
for ,1% of all colorectal cancer (CRC) cases. The
syndrome is characterised by the development of
hundreds to thousands of adenomas in the colorectum.
Almost all patients will develop CRC if they are not
identified and treated at an early stage. The syndrome is
inherited as an autosomal dominant trait and caused by
mutations in the APC gene. Recently, a second gene has
been identified that also gives rise to colonic adenoma-
tous polyposis, although the phenotype is less severe than
typical FAP. The gene is the MUTYH gene and the
inheritance is autosomal recessive. In April 2006 and
February 2007, a workshop was organised in Mallorca by
European experts on hereditary gastrointestinal cancer
aiming to establish guidelines for the clinical management
of FAP and to initiate collaborative studies. Thirty-one
experts from nine European countries participated in these
workshops. Prior to the meeting, various participants
examined the most important management issues
according to the latest publications. A systematic
literature search using Pubmed and reference lists of
retrieved articles, and manual searches of relevant
articles, was performed. During the workshop, all
recommendations were discussed in detail. Because most
of the studies that form the basis for the recommenda-
tions were descriptive and/or retrospective in nature,
many of them were based on expert opinion. The
guidelines described herein may be helpful in the
appropriate management of FAP families. In order to
improve the care of these families further, prospective
controlled studies should be undertaken.
In about 5% of all cases, colorectal cancer (CRC) is
associated with a dominantly or recessively inher-
ited syndrome due to mutations in high penetrance
genes. The most common syndrome is Lynch
syndrome (hereditary non-polyposis colorectal
cancer (HNPCC)), which is characterised by the
development of CRC, endometrial cancer and
various other cancers.1 The syndrome is caused
by a mutation in one of the mismatch repair
(MMR) genes: MLH1, MSH2, MSH6 and PMS2.
Familial adenomatous polyposis (FAP) is another
well-described inherited syndrome, which is
responsible for 1% or less of all CRC cases.2 This
syndrome is characterised by the development of
hundreds to thousands of adenomas in the color-
ectum as well as several extracolonic manifestations.
Almost all patients will develop CRC if they are not
identified and treated at an early stage.3
Approximately 8% of families with FAP display an
attenuated form of FAP characterised by the devel-
opment of fewer adenomas and CRC at a more
advanced age.4 The syndrome, when inherited in an
autosomal dominant manner, is caused by mutations
in the APC gene. This gene plays a central role in the
development and homeostasis of the intestine and
many other tissues. Recently another polyposis gene
has been identified, the MUTYH gene, in which bi-
allelic mutations cause an autosomal recessive
pattern of inheritance.5 This form of polyposis is
usually referred to as MUTYH-associated polyposis
(MAP).
In April 2006 and February 2007, a workshop
was organised for a group of European experts on
hereditary gastrointestinal cancer. The main pur-
pose was to develop guidelines for the clinical
management of the most common inherited forms
of CRC and to establish collaborative studies. A
total of 31 experts from nine European countries
participated in the workshops. These experts
included clinical and molecular geneticists, sur-
geons, gastroenterologists and a pathologist all
involved in the management of hereditary CRC.
Prior to the meetings, key questions for important
management issues were identified and a literature
search was performed in order to address these
questions and to elaborate guidelines in the light of
the most recent knowledge. Here we report the
outcome of the discussion with respect to FAP.
Search terms included familial adenomatous poly-
posis (FAP), MUTYH-associated polyposis (MAP),
APC gene and M(UT)YH gene. Only peer-reviewed
English language articles were included. The
criteria that were used for evaluation of studies
and assessment of the category of evidence and
strength of the recommendation are shown in
table 1. During the workshop, all recommenda-
tions were discussed in detail.
CHARACTERISTICS OF APC-ASSOCIATED FAP
FAP is an autosomal dominant condition caused
by APC mutations that occurs in 1 in 10 000
births.6 In 15–20%, the cases are ‘‘de novo’’
without clinical or genetic evidence of FAP in the
parents.7 Recent studies indicated the presence of
mosaicism in approximately 15% of such cases.8 9
Most patients develop hundreds of colorectal
adenomas during childhood and adolescence.
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Without surgical intervention they almost inevitably develop
CRC by the mean age of 40–50 years. A milder form of FAP
(attenuated FAP, AFAP) characterised by the presence of fewer
adenomas and later onset of disease is observed in approxi-
mately 8% of cases.10 Adenomatous polyps also develop in the
upper gastrointestinal tract, especially in the duodenum, and, if
untreated, these progress to malignancy in approximately 5% of
cases.11 Gastric fundic gland polyps and adenomas in the antrum
also occur. There are a few case reports12 13 of gastric cancer in
FAP, especially from Japan and Korea, but substantial evidence
of an increased risk in FAP patients from Western countries is
not available. The incidence of gastric cancer in large national
polyposis registries does not support the hypothesis of an
increased risk, but only future large multicentre studies can
clarify if the known cases represent an increased risk or mere
coincidence. There is an increased risk of malignancy at other
sites including the brain, thyroid and the liver. Deregulation of
the APC gene has been shown to play a role in carcinogenesis in
all of these tissues. Desmoid tumours occur in at least 10–15%
of cases.14 Although these tumours of connective tissue are
histologically benign, they can lead to life-threatening complica-
tions through their size and impingement on vital structures.
Other features observed in FAP are shown in table 2.
The standard clinical diagnosis of typical/classical FAP is
based on the identification of .100 colorectal adenomatous
polyps. The clinical diagnosis of AFAP is more difficult.
Recently, diagnostic criteria for AFAP have been proposed by
Nielsen et al4 and by Knudsen et al (presented at the meeting of
the International Society of Gastrointestinal Hereditary
Tumours (InSiGHT), Yokohama 2007). According to the criteria
suggested by Nielsen, there should be (1) at least two patients
with 10–99 adenomas at age .30 years or (2) one patient with
10–99 adenomas at age .30 years and a first-degree relative
with CRC with few adenomas; for both criteria, no family
members with.100 adenomas before the age of 30 years. Based on
a multicentre study of 196 patients, Knudsen et al10 proposed the
following diagnostic criteria for AFAP: (1) a dominant mode of
inheritance and (2) 3–99 colorectal adenomas at age 20 or older
(presented at the meeting of the International Society of Gastro-
intestinal Hereditary Tumours (InSiGHT), Yokohama 2007).
In more than 70% of patients with typical FAP, a mutation
can be identified in the APC gene. The yield of APC gene
mutations is much lower in patients with AFAP (,25%).4
Genetic counselling and mutation analysis should be offered
to all patients with FAP. If a pathogenic mutation has been
identified in the index patient, predictve testing for the
mutation should be offered to the first-degree relatives. In
typical FAP, family members that are found to carry the
mutation should be advised to undergo periodic examination of
the rectosigmoid from the early teens, and of the upper
gastrointestinal tract from age 25–30 years to monitor adenoma
development. The treatment of colonic polyposis consists of
colectomy or proctocolectomy usually once florid polyposis has
developed. The treatment of duodenal adenomas depends on
the severity of the disease.
SURVEILLANCE OF THE COLORECTUM
QUESTION: does periodic examination of the colorectum lead to
early detection of FAP and reduction of CRC-associated mortality?
A literature search showed that at least five studies have
addressed the first part of the question.15–19 These studies
decribed the results of polyposis registers that were established
in various countries mostly in the 1980s and 1990s in order to
improve the prognosis of patients with this disease. All studies
showed that in symptomatic FAP cases, the incidence of CRC
was much higher (incidence: 50–70%) than in those that were
identified by surveillance (incidence: 3–10%) initiated by the
registries. Other studies that evaluated the mortality of patients
with FAP reported that surveillance policies and prophylactic
colectomy have resulted in a reduction in the number of FAP
patients that died from CRC but that, nowadays, a greater
proportion of deaths is attributable to extracolonic manifesta-
tions of the disease (desmoid tumours, duodenal cancer).20–22 At
least three studies have indicated that central registration and
prophylactic examination led to a reduction of CRC-associated
mortality.23–25
CONCLUSION: surveillance of FAP patients leads to reduction of
CRC and CRC-associated mortality (category of evidence III).
QUESTION: what is the optimal surveillance protocol in terms of
timing, type of investigation and surveillance interval in patients with
classical FAP and AFAP?
Classical (typical) FAP
The age at which screening should start depends on the risk of
malignant transformation of the colorectal adenomas.26 In the
recent literature there are no studies that provide information
on the distribution of the ages at diagnosis of CRC in FAP
because most cases are currently diagnosed in a premalignant
stage. Studies on large series of FAP families from the 1970s and
1980s indicated that the risk of developing CRC before age 20 is
very low.16 The proportion of FAP patients with CRC diagnosed
at (20 years of age observed in some European registries is
shown in table 3.
There were no cases of CRC at or before the age of 10 years,
and an incidental case between age 11 and 15 years. Based on
these findings, the European group advises starting endoscopic
surveillance from the early teens. Since some patients, especially
those with a mutation located at codon 1309 in the APC gene
(see below), may develop severe polyposis of the colorectum
before the age of 10, attention must be paid to FAP-related
symptoms.27 These symptoms may include increasing bowel
Table 1 Validity and grading of recommendations
Category of evidence
Grading of
recommendations
Meta-analysis of randomised controlled
trials
Ia A
Randomised controlled trial Ib
Well-designed controlled study without
randomisation
IIa B
Well designed quasi-experimental study IIb
Non-experimental descriptive study III
Expert opinion IV C
Table 2 Extra-intestinal features in familial adenomatous
polyposis
Benign lesions Malignant lesions
Congenital hypertrophy of the retinal
pigmented epithelium (70–80%)
Thyroid cancer (2–3%)
Epidermoid cysts (50%) Brain tumour (,1%)
Osteoma (50–90%) Hepatoblastoma (,1%)
Desmoid tumour (10–15%)
Supernumerary teeth (11–27%)
Adrenal gland adenomas (7–13%)
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movements, looser stools, mucous discharge, rectal bleeding,
abdominal or back pain. In symptomatic patients, endoscopic
investigation may be indicated at any age.
In family members with an identified mutation, endoscopic
surveillance should be continued lifelong because the penetrance
of the disease is virtually 100%. In high risk members (first-degree
relatives of affected patients) from families without an identified
APC mutation, surveillance should be continued until age 50.
The second question is which part of the colorectum should
be investigated. Only one study was found that specifically
addressed this question. In that study, Bussey demonstrated
that in 170 patients with FAP, the rectum was affected in all
cases.16 Based on these studies it is sufficient to perform flexible
sigmoidoscopy, at least initially. Once adenomas are identified
with sigmoidoscopy, there is an indication for full colonoscopy.
Regarding the interval between examinations, studies on the
natural history of FAP showed that it takes on average 15–20
years from the first development of adenomas to the develop-
ment of malignancy.16 Therefore, an interval of 2 years between
normal sigmoidoscopies is appropriate. If adenomas are
detected, colonoscopic investigations should be performed
annually until colectomy is planned. In high risk members
(first-degree relatives of affected patients) from families without
an identified APC mutation, surveillance should be continued at
2-yearly intervals until age 40. After this age the intervals
between examinations may be longer—for example, every 3–5
years—and surveillance may be discontinued at age 50.
AFAP
In families with AFAP, a different protocol is recommended. A
recent Dutch study on nine AFAP families associated with APC
mutation reported a mean age at diagnosis of CRC of 54 years
(n = 40) which is about 10–15 years later than in classical FAP.
No cases of CRC were observed in individuals younger than 20
years. The youngest case of CRC was diagnosed at age 24 years.4
In an American study of a large family with AFAP, no CRC was
observed in patients under the age of 29 years.28 Therefore,
periodic examination is recommended starting from age 18–20.
Because patients with AFAP have been described that develop
only a few adenomas localised in the right part of the colon,
colonoscopy is recommended instead of sigmoidoscopy.
CONCLUSION: the suggested surveillance protocol for patients
with classical and attenuated FAP is summarised in table 4 (category
of evidence III, grade of recommendation B)
MANAGEMENT OF COLONIC POLYPOSIS
Removal of the colon with polyposis at a premalignant stage is
very important because it prevents the significant morbidity
and mortalitiy associated with advanced CRC.
QUESTION: which surgical procedure is the best option for
patients with FAP?
The two main options of prophylactic removal of the large
intestine are colectomy with ileorectal anastomosis (IRA) and
proctocolectomy with ileal pouch–anal anastomosis (IPAA).
IRA is a relatively simple and straightforward operation,
compared with IPAA. The complication rate is relatively low
and the bowel function postoperatively is almost always good.
For IPAA, more extensive surgery is needed including pelvic
dissection with its risk of haemorrhage, reduction of fertility in
women and potential damage to pelvic nerves.29 Recently, a
meta-analysis by Aziz et al has been published of studies that
compared adverse effects, functional outcome and quality of life
between the two options.30 The authors selected 12 studies
containing 1002 patients with FAP. They reported that bowel
frequency, night defecation and use of incontinence pads were
significantly less in the IRA group, although faecal urgency was
more frequent with IRA compared with IPAA. Reoperation
within 30 days was more common after IPAA. There was no
significant difference between the procedures in terms of sexual
dysfunction, dietary restriction or postoperative complications.
Rectal cancer was only observed in the IRA group (5%). In
addition, abdominal reoperation on the rectum was more
frequent after IRA (28%) versus IPAA (3%). The study
demonstrated the individual merits and weaknesses of IRA
and IPAA.
An IPAA is the treatment of choice if the patient has a large
number of rectal adenomas—for example more than 15–20
adenomas. In patients with only a few rectal adenomas or with
a polyp-free rectum, both options are possible and the decision
can be made on an individual basis.
Several studies have shown that the severity of colonic
polyposis is correlated with the site of the mutation in the APC
Table 3 Proportion of FAP patients with CRC diagnosed at (20 years of age*
Polyposis registry Total number of CRCs
Number of CRCs (%) diagnosed
0–10 years 11–15 years 16–20 years
The Netherlands 106 0 1 1
Denmark 190 0 0 3
Germany 524 0 1 7
St Mark’s 96 0 0 3
Finland 157 0 0 1
Total 1073 0 2 (0.2%) 15 (1.3%)
*Communicated with registries.
CRC, colorectal cancer, FAP, familial adenomatous polyposis.
Table 4 Colorectal surveillance protocol in family members at risk for (A)FAP
Type of investigation Lower age limit Interval
Classical FAP Sigmoidoscopy* 10–12 years 2 years*
AFAP Colonoscopy 18–20 years 2 years*
*Once adenomas are detected annual colonoscopy should be performed until colectomy is planned.
(A)FAP, (attenuated) familial adenomatous polyposis.
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gene. These studies have recently been reviewed by
Nieuwenhuis et al.31 The evaluation showed that mutations
between codons 1250 and 1464, especially those with a
mutation at codon 1309, are associated with a severe form of
FAP, mutations localised at the extreme ends of the gene and in
the alternatively spliced part of exon 9 are associated with a
mild from of FAP, and an intermediate expression of disease is
found in patients with mutations in the remaining parts of the
gene. Several authors have proposed to use the outcome of
genetic testing in guiding the surgical treatment of patients
with a relatively polyp-free rectum.32–36 An IPAA may be advised
in patients with a severe genotype because such patients are at
increased risk of developing severe rectal polyposis that will
require a secondary proctectomy if IRA is performed.33–35 An IRA
is indicated in those with a mild genotype because of the low
risk of developing severe rectal polyposis.35 36 However, a
consensus has not yet been reached by the Mallorca group, or
more widely, on use of genotype as a decision aid to guide the
choice of IRA or IPAA in patients with FAP who have no or
little evidence of rectal polyposis.37
Other factors that should be taken into account are fertility
and desmoid development. Studies reported that fertility was
significantly reduced after IPAA compared with IRA in women
with FAP.38 Therefore, in young women who wish to have
children, an IPAA should be avoided or postponed, if possible. In
patients with desmoids it has been reported that conversion of
IRA to IPAA might be difficult due to (asymptomatic)
mesenteric desmoid tumours and shortening of the mesentery.
For this reason, a primary IPAA might be the best option in
patients with an increased risk of desmoid development—for
example, patients with a positive family history for these
tumours or patients with a mutation located distal to codon
1444. Some members of the Mallorca group noted, however,
that patients with mutations 39 of 1444 often have mild
polyposis, and performing an IPAA might be overtreatment.
In conclusion, the decision on the type of surgery depends on
many factors. It should be emphasised that the final decision on
the type of surgery lies with the patient after being fully
informed about the natural history of the disease and the pros
and cons of the main surgical options.
There are no guidelines regarding the timing of surgery. In
general, a (procto)colectomy is indicated if there are large
numbers of adenomas .5 mm, including adenomas showing a
high degree of dysplasia. Most patients with classical FAP
undergo surgery between age 15 and 25 years.
The frequency of endoscopic follow-up of the rectum
after IRA depends on the severity of rectal polyposis. The
recommended interval varies between 3 and 6 months. In
patients with multiple large (.5 mm) rectal adenomas that
show a high degree of dysplasia there is an indication for
proctectomy. Because patients with IPAA may also develop
adenomas and even cancer in the pouch, follow-up is indicated
after this procedure at intervals of 6–12 months.39–42
CONCLUSION: the main surgical options of removal of the
colorectum—that is, total colectomy with ileorectal anastomosis (IRA)
and proctocolectomy with ileal pouch–anal anastomosis (IPAA)—both
have their individual merits and weaknesses. The decision on the type
of colorectal surgery in patients with FAP depends on many factors
including the age of the patient, the severity of rectal (and colonic)
polyposis, the wish to have children, the risk of developing desmoids
and possibly the site of the mutation in the APC gene. The final
decision lies with the patient after being fully informed about the
natural history of the disease and the pros and cons of the available
surgical options. The group advises that IPAA should preferably be
performed in expert centres.
SURVEILLANCE OF THE DUODENUM
Many studies have shown that adenomas in the duodenum can
be found in 50–90% of cases.43 44 Age appears to be the most
important risk factor. There is no clear association between site
of the mutation and development of (severe) duodenal
polyposis. In most studies, the severity of duodenal polyposis
is assessed using the Spigelman classification.45 This system
describes five (O–IV) stages (table 5). Points are accumulated for
number, size, histology and severity of dysplasia of polyps.
Stage I (1–4 points) indicates mild disease, whereas stage III–IV
(.6 points) implies severe duodenal polyposis. Approximately
80% of the patients have stage I–III disease and 10–20% have
stage IV disease.
QUESTION: does periodic examination of the upper gastrointest-
inal tract lead to detection of duodenal polyposis in an early stage?
There are three prospective studies of surveillance of the
duodenum (table 6).44 46 47 These studies demonstrated slow
progression of duodenal polyps in size, number and histology.
The risk of developing cancer appears to be related to the
Spigelman stage. In the British study,46 4 out of 11 patients with
stage IV disease at initial examination developed cancer, as did
one out of 41 patients with initially stage III disease. In the
Scandinavian–Dutch study,44 2 out of 27 patients with stage IV
disease at the first endoscopy developed cancer compared with 2
out of 339 (,1%) with stage 0–III. The cumulative risk of
duodenal cancer at age 57 was 4.5%.
CONCLUSION: prospective follow-up studies on the natural
history of duodenal polyposis have demonstrated that the adenomas
progress slowly to cancer. Because the conversion from adenomas to
carcinoma may take more than 15–20 years, current screening
protocols of the upper gastrointestinal tract usually detect duodenal
disease at a premalignant stage (category of evidence III).
Table 6 The progression of duodenal polyposis in familial adenomatous
polyposis
Author Groves Saurin Bulow
Year of publication 2002 2004 2004
Subjects 99 35 368
Mean age (years) 42 37 25
Sex (% male) 55 57 49
Mean follow-up (years) 10 4 7.6
Spigelman stage IV
at initial examination 9.6% 14% 7%
at last follow-up 14% 35% 15%
Duodenal cancer during follow-up 6* 0 4{
*Spigelman stage at previous endoscopy: II, III, IV, IV, IV, IV.
{Spigelman stage at previous endoscopy: II, III, IV, IV.
Table 5 Spigelman classification for duodenal polyposis in familial
adenomatous polyposis
Criterion 1 point 2 points 3 points
Polyp number 1–4 5–20 .20
Polyp size (mm) 1–4 5–10 .10
Histology Tubular Tubulovillous Villous
Dysplasia Mild* Moderate* Severe{
Stage 0, 0 points; stage I, 1–4 points; stage II, 5–6 points; stage III, 7–8 points; stage
IV, 9–12 points.
*A low degree of dysplasia according to current classification.
{A high degree of dysplasia.
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MANAGEMENT OF DUODENAL POLYPOSIS
QUESTION: does treatment of premalignant duodenal lesions lead to
a reduction of mortality related to duodenal cancer?
In the literature, there are no studies in which surveillance
and treatment of duodenal disease is compared with a strategy
of no surveillance. Although the overall risk of developing
duodenal cancer in all patients with FAP is relatively low
(,5%),11 the risk of developing cancer in patients with
Spigelman stage III–IV duodenal adenomatosis is much higher
(7–36%).44 46 Identification of such patients is important because
particularly this category of patients might benefit from
intensive surveillance and early treatment.
The options of treatment are endoscopic and surgical.
Endoscopic treatment includes snare excision, thermal ablation,
argon plasma coagulation or photodynamic therapy. There are
only a few studies that evaluated the outcome of endoscopic
treatment. These studies have recently been reviewed by
Brosens et al.48 The review demonstrated that the recurrence
rate of adenoma development after endoscopic treatment is
high (.50%) and that the treatment is associated with a high
complication rate (perforation, haemorrhage, pancreati-
tis)(17%).
There is no consensus about how to treat patients with
duodenal polyposis. In patients with only a few small adenomas
(Spigelman stage I and II), the risk of developing duodenal
cancer is very low and, in view of the potential serious
complications associated with (endoscopic) treatment, the
management may be limited to follow-up.
In patients with multiple larger adenomas (Spigelman stage
III or more), the risk of duodenal cancer is higher. Because it is
impossible to remove all adenomas, an appropriate approach
might be to remove only large adenomas—for example, those of
.1 cm in diameter—or adenomas with a high degree of
dysplasia. However, duodenal adenomas are usually flat and
therefore difficult to remove. For these cases prior submucosal
saline/adrenaline injection may facilitate removal and reduce
the risk of haemorrhage and perforation. Although the value of
endoscopic treatment of patients with stage II and III is
unknown, a possible advantage of endoscopic treatment is that
it may delay major intervention (eg, Whipple’s procedure)
which is associated with a significant morbidity (20–30%) and
even mortality. The Mallorca group advises centralisation of
such treatment in a few expert centres.
The options for surgical treatment of duodenal polyposis in
FAP include local surgical treatment (duodenotomy with
polypectomy and/or ampullectomy), pancreas-sparing duode-
nectomy and (pylorus-sparing) pancreaticoduodenectomy
(Whipple’s procedure). At least 11 studies, also reviewed by
Brosens et al, evaluated the outcome of local treatment of
duodenal polyposis.48 Most studies reported a high recurrence
rate after local surgery in FAP patients with severe polyposis.
The most important advantage of this treatment is that it may
postpone major surgery in young patients. Duodenotomy might
be especially useful in patients with one or two dominant
worrisome duodenal lesions in an otherwise minimally involved
intestine.
In patients with stage IV disease found at repeated
endoscopic examinations, there is an indication for pancreati-
coduodenectomy or a pancreas-sparing duodenectomy. Brosens
et al identified 12 studies that evaluated the outcome of this
treatment. All studies showed that the recurrence rate of
adenomas (in the proximal small bowel) was relatively low.
However, in order to be able to investigate this part of the small
bowel after surgery, the Roux-Y should be constructed in such a
way that endoscopic follow-up is possible. The specific choice of
procedure depends on the local expertise.
CONCLUSION: screening of the duodenum in patients with
FAP may lead to the identification of patients with advanced
duodenal disease (Spigelman stage III/IV). Intensive surveillance
and treatment of such patients may lead to reduction of duodenal
cancer-related mortality (category of evidence III/IV). In young
patients (,40 years) with advanced disease (stage III/IV), local
surgery (duodenotomy and polypectomy) might be of benefit to
postpone major surgery. In older patients with stage IV disease at
repeated examinations, there is an indication for duodenectomy
(category of evidence IV, grade of recommendation C).
QUESTION: what is the appropriate protocol in terms of timing,
type of investigation and surveillance interval?
There is no consensus in the literature regarding the age at
which upper gastrointestinal tract surveillance should be
initiated. Some authors advise to start at the diagnosis of FAP,
others from the age of 25–30 years. Evaluation of all cases of
duodenal cancer reported in the literature showed that diagnosis
before age 30 years is extremely rare.48 Therefore, the Mallorca
group recommends to start from an age between 25 and 30
years. Most centres recommend the use of a side-viewing
endoscope to allow detailed inspection of the papilla, the
predelicted site for duodenal polyposis. However, in the early
Spigelman stages, the use of a forward-viewing endoscope
might also be appropriate. The recommended intervals between
screening depend on the severity of disease (table 7).44 46
CONCLUSION: the Mallorca group recommends that surveillance
of the upper gastrointestinal tract be initiated between age 25 and 30
years. The suggested protocol is shown in table 7 (category of
evidence IV, grade of recommendation C).
MANAGEMENT OF DESMOID TUMOURS
QUESTION: what is the appropriate treatment of desmoid tumours?
A substantial number of FAP patients (at least 10–15%)
develop desmoid tumours. Possible risk factors include abdom-
inal surgery, positive family history for desmoids and site of the
mutation (mutations beyond codon 1444).14 49–51 In contrast to
sporadic desmoid tumours, the majority of the tumours
associated with FAP are located in the abdominal wall or
intra-abdominally. The tumours can be diagnosed by CT
scanning or MRI. The latter procedure may also provide
information on the activity of the tumour. Desmoid tumours
are also frequently encountered incidentally in patients requir-
ing further surgery. The options for treatment are pharmaco-
logical treatment (non-steroidal anti-inflammatory drugs
(NSAIDs) and/or anti-oestrogens), chemotherapy, surgical
excision or radiotherapy.52–54 Evidence for the efficacy of these
treatments is poor and is based on small, non-controlled studies.
An additional problem for the evaluation of efficacy is that
desmoids have a variable natural history, with some tumours
showing spontaneous regression in the absence of treatment.
Table 7 Recommended surveillance interval between
upper gastrointestinal endoscopic examination in relation
to Spigelman classification
Spigelman classification Surveillance interval (years)
0/I 5
II 3
III 1–2
IV Consider surgery
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In 2003, Janinis et al performed a systematic review of
published clinical trials, studies and case series that reported the
effectiveness of pharmacological treatment of desmoid
tumours.55 The authors concluded that the evidence in the
literature supports the opinion that both non-cytotoxic and
cytotoxic chemotherapies are effective against desmoid
tumours. However, the lack of sufficient patient numbers and
randomised trials compromises the validity of the reported
results and mandates further investigation with prospective
studies including larger patient numbers.
In 2000, a review of the literature was published on the
effectiveness of surgery compared with radiation therapy for
(non-FAP) patients with desmoid tumours.56 The study showed
that radiation therapy alone or in combination with surgery
resulted in significantly better control than surgery.
Currently, the first line of treatment in patients with large or
growing intra-abdominal or abdominal wall tumours is sulindac
(300 mg) usually in combination with tamoxifen (40–120 mg)
or toremifene (180 mg).52–54 57 In patients with progressive intra-
abdominal tumours that do not respond to this treatment,
chemotherapy (eg, doxorubicine and dacarbazine or methotrex-
ate and vinblastine)58 59 or radiation therapy is indicated. The
preferred treatment of patients with an abdominal wall
desmoid tumour is controversial. Some authors consider surgery
of abdominal wall desmoid tumours as a reasonable first-line
treatment in these cases.54 Others do not recommend surgery as
primary treatment because most especially large tumours
cannot be resected and the recurrence rate is high.60 There is
also no agreement about the role of surgery for mesenteric
desmoids. Some investigators consider surgery contraindicated
because of the risk of severe complications (short bowel
syndrome, severe bleeding) or because surgery may trigger
further growth of the tumour.52 60 These investigators recom-
mend only minimal surgery (intestinal bypass) in patients with
obstruction or advise stenting of the ureter in patients with
ureteric involvement. Others, however, reported succesful
excision of large mesenteric desmoids with low mortality and
limited loss of the small bowel,61 62 and consider that resection
of mesenteric desmoids in experienced hands may have a role in
the treatment of selected patients unresponsive to conservative
treatment
CONCLUSION: non-randomised, non-controlled studies suggest
that sulindac in combination with tamoxifen is effective in FAP
patients with intra-abdominal desmoids and desmoids located at the
abdominal wall (category of evidence III). Also small non-controlled
studies indicate that chemotherapy or radiotherapy may be of benefit
in those with progressive growing desmoids (category of evidence III).
The role of surgery of (intra)-abdominal-(wall) tumours is
controversial (category of evidence III)
PHARMACOLOGICAL TREATMENT
QUESTION: what is the role of NSAIDS in the treatment of
colorectal and duodenal adenomas in FAP?
The first drug that was shown to be effective in FAP was
sulindac.63–66 Long-term use of this drug reduced the number of
colorectal adenomas by .50% in the colon as well as in the
retained rectal segment of FAP patients after initial colect-
omy.63–67 However, sulindac did not prevent development of
adenomas in FAP.68
In the 1990s, selective COX-2 (cyclo-oxygenase-2) inhibitors
were developed that were reported to have fewer (gastrointest-
inal related) side effects than the classical non-selective NSAIDs.
One of these drugs (celecoxib) was found to reduce the number
of colorectal adenomas by 28%.69 In contrast to sulindac, this
drug also reduced the number of duodenal adenomas.70
Unfortunately, cardiovascular side effects have recently been
reported in patients using another selective COX-2 inhibitor,
rofecoxib. In a trial involving 2600 patients with colon polyps,
3.5% of the patients assigned to rofecoxib had a myocardial
infarction or stroke, as compared with 1.9% of the patients
assigned to placebo, necessitating premature cessation of the
trial.71 72 A recently published meta-analysis of different NSAIDs
confirmed the increased risk of cardiovascular diseases with
rofecoxib.73 The analysis included 11 studies that reported on
celecoxib. It was found that celecoxib exposure in a dose of
around 200 mg per day did not lead to an elevation of the risk of
cardiovascular disease, but the data did not exclude an increased
risk with higher doses which are usually indicated in FAP.
Celecoxib (onsenal) is registered for the treatment of FAP in
several countries, but some specialists who are dealing with the
management of FAP patients are reluctant to prescribe these
drugs, especially because most patients have to use the drug in
high doses on a long-term basis. Data are currently being
collected on a worldwide basis to evaluate the effect and
possible side effects of the long-term use of celecoxib in patients
with FAP.
Although NSAIDs do not replace surgical treatment for
colonic FAP, they may yet play a role in postponing surgery in
patients with mild colonic polyposis or patients with rectal
polyposis after prior colectomy. They may also be used in
patients who refuse surgical treatment or in patients that
cannot be operated on because of extensive desmoid disease.
Although the effect of celecoxib on the number of colorectal
adenomas has never been directly compared with the effect of
sulindac, the published trials suggest a stronger effect of the
latter. In addition, an association of sulindac with serious
cardiovascular side effects has never been reported, and the
gastrointestinal-related toxicity can be treated with proton
pump inhibitors if necessary. Based on these considerations, one
may argue that sulindac is more attractive than celecoxib for the
treatment of colorectal adenoma.
Regarding the treatment of duodenal polyposis, the use of
celecoxib might be justifiable for patients with severe duodenal
polyposis (Spigelman stage III or IV), because the endoscopic
and surgical treatment options in such cases are associated with
significant complications.
CONCLUSION: chemoprevention with NSAIDs can be considered
in patients following initial prophylactic surgery as an adjunct to
endoscopic surveillance, to reduce the rectal polyp burden. The role of
selective COX-2 inhibitors in patients with FAP is controversial
because of cardiovascular side effects reported for rofecoxib. Therefore,
these drugs should only be considered in selected patients without
cardiovascular risk factors until more data are available.
MUTYH-ASSOCIATED ADENOMATOUS POLYPOSIS (MAP)
In 2002, Al-Tassan et al demonstrated a role for defective base
excision repair (BER) in hereditary colorectal cancer.5 They
identified bi-allelic germline mutations in the BER gene MUTYH
in a British family with three affected members and recesssive
inheritance of multiple colorectal adenomas and carcinoma.
Further studies found bi-allelic MUTYH mutations in 26–29% of
patients with 10–100 polyps and 7–29% of patients with 100–
1000 polyps.74–76 Bi-allelic mutations have rarely been reported in
patients with fewer than 10 adenomas, and in some apparently
CRC-only patients.77 78 Based on these findings, patients with
more than 10 adenomas should be referred for genetic
counselling, and mutation analysis of the MUTYH gene
should be considered. Bi-allelic MUTYH mutations are usually
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associated with an attenuated polyposis phenotype. To date,
other intestinal malignancies and FAP-associated extraintestinal
lesions such as duodenal cancer, osteomas and CHRPE (con-
genital hypertrophy of the retinal pigment epithelium) have
been reported only sporadically in MAP patients.79 80 Family
members with mono-allelic mutations in MUTYH are probably
not at increased risk of CRC, and therefore do not need
colonoscopic surveillance.81
QUESTION: which surveillance protocol should be recommended to
patients with FAP due to bi-allelic MUTYH mutations?
The decision regarding the age at which screening should
start is based on the distribution of ages at diagnosis of CRC.
CRC due to bi-allelic MUTYH mutations before the age of 30
years has been reported only once.79 Therefore, it appears
justified to start screening from the same age as recommended
in AFAP (between 18 and 20 years). Because patients may
develop only a few adenomas and CRC is often localised in the
proximal part of the colon, the Mallorca group recommend
performing colonoscopy at 2-yearly intervals instead of sigmoi-
doscopy. Upper gastrointestinal endoscopy is advised starting
from between 25 and 30 years of age. The recommended
intervals between screening depend on the severity of disease
(table 7).
CONCLUSION: the suggested surveillance protocol for MAP
patients is similar to that for patients with AFAP (category of evidence
III, grade of recommendation B) (see table 4).
QUESTION: what is the approprate surgical treatment of colonic
polyposis in carriers of bi-allelic MUTYH mutations?
Most patients with bi-allelic MUTYH mutations have an
attenuated phenotype.76 79 Because of the small number of
adenomas, in some patients it is possible to remove these polyps
endoscopically. If surgery is required, an IRA will be sufficient in
most cases to eliminate the cancer risk. However, if rectal
polyposis is severe, an IPAA is advised.
DISCUSSION
The guidelines for the management of FAP presented here are
the result of intensive discussions among the participants of
two workshops held in Mallorca in 2006 and 2007. Because
most of the studies that form the basis for the guidelines were
descriptive and/or retrospective in nature, many of the
recommendations were based on expert opinion.
The identification of a mutated APC gene as the cause of FAP
in the early 1990s allowed presymptomatic diagnosis in families
with an identified mutation. As a consequence, those indivi-
duals that were found not to carry the mutation could be
reassured and surveillance could be discontinued. Another way
in which genetic information might be translated into clinical
practice is in the decision-making process of surgical treatment.
Studies have shown that the site of the mutation in the APC
gene may predict the risk of developing severe rectal polyposis
and the need for subsequent proctectomy if a patient had
colectomy with IRA. Using this genetic information, individuals
may be identified with a low or high risk of developing
significant rectal polyposis, and this can help in the decision
between IRA and IPAA in difficult cases. However, the use of
genetic information in the surgical decision making is con-
troversial, because several studies have reported intrafamilial
variation, which might be due to environmental factors or
modifier genes. Moreover, in many patients, a previously
unknown (private) mutation is identified which cannot be used
to predict the future course of the colorectal phenotype.
Therefore, future prospective studies should be done to evaluate
the utility of this genetic information in surgical practice.
In undiagnosed cases of FAP, the leading cause of death is
colorectal cancer. The establishment of registries of FAP families
worldwide has encouraged participation in surveillance pro-
grammes and has significantly reduced death from CRC.
Nowadays, the prognosis of FAP patients appears to be
increasingly determined by extracolonic features of FAP,
especially duodenal cancer and desmoid tumours. Future studies
should therefore focus on how the management of these
tumours can be improved.
Regarding duodenal polyposis, a few prospective studies have
shown that the Spigelman classification can be used to identify
patients who are at high risk of developing duodenal cancer.
However, the risk of developing duodenal cancer reported for
patients with Spigelman stage IV varied greatly between these
studies. Therefore, additional risk factors should be sought
which can predict the development of duodenal cancer more
precisely. The knowledge of such risk factors may also be
helpful in decisions regarding the choice between local (endo-
scopic or surgical) treatment or a more definitive treatment such
as duodenectomy. Ideally, the latter option should be reserved
for those patients with a high risk of developing duodenal
cancer, while local treatment may be indicated in those with a
low risk.
All studies on the efficacy of drugs for desmoid tumours have
been small and non-controlled. Therefore, randomised con-
trolled trials are needed to evaluate the effectiveness of the
drugs that are currently used. Several studies have shown that
surgery for colonic polyposis constitutes a risk factor for
development of desmoid tumours. Future studies should address
whether prophylactic treatment with sulindac and tamoxifen
for 6 or 12 months postoperatively decreases the risk of desmoid
tumours, especially in those patients with an increased risk of
desmoids.
A possible way to improve the prognosis of patients with FAP
further is early detection and treatment of the less common
extraintestinal cancers which are seen with increased frequency
in individuals with FAP (see table 2). It has been reported that
female FAP patients have a 2–3% lifetime risk of developing
thyroid cancer.82 Based on these figures, some investigators have
recommended surveillance of the thyroid by palpation and
ultrasound, especially in women with FAP.83 84 However, other
investigators consider the risk too low to justify such a
programme.85 Surveillance for hepatoblastoma is also contro-
versial. The risk for these tumours is about 1%, and most
tumours develop in the first year of life, with a predominance in
males.86 Future studies should evaluate whether surveillance
programmes for thyroid cancer and hepatoblastoma in FAP are
effective and whether any gain in life expectancy outweighs the
potential psychosocial problems that may result.87 Small bowel
cancers located distal to the ligament of Treitz have occasionaly
been reported in FAP. In view of the development of new
techniques for visualisation of the small bowel (videocapsule
endoscopy, double balloon endoscopy) in recent years, the
question arises of whether surveillance of the small bowel might
be useful. In order to answer this question, studies are needed
that evaluate the lifetime risk of developing such tumours.
The ideal treatment of patients with FAP would be
pharmacological. Several studies have shown sulindac to be
effective in reducing colorectal adenomas. Celecoxib is the only
drug that has been shown to be effective in reducing duodenal
adenomatosis. In view of the serious cardiovascular side effects
that have been reported in patients using one of the other
selective COX-2 inhibitors (rofecoxib), some specialists are
reluctant to prescribe celecoxib. However, provided that
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patients are screened for cardiovascular risk factors, the use of
COX-2 inhibitors may be justifiable in special situations—for
example, in patients with severe duodenal polyposis (Spigelman
III and IV). Future studies should evaluate whether the
potential risk of cardiovascular side effects of celecoxib is
significant in view of the possible use of these agents to reduce
the cancer risk and avoid the morbidity and mortality associated
with the endoscopic and surgical treatment for duodenal
polyposis.
Finally, it has to be taken into account that although NSAIDs
have been shown to reduce the number of adenomas, it has
never been proven that these drugs also prevent the develop-
ment of CRC. This is an important question because patients
have been reported that developed cancer whilst being treated
with NSAIDs, despite showing reduction of the size and
number of rectal adenomas.88
In conclusion, the guidelines described here may be helpful in
the appropriate management of families with FAP. In order to
improve further the care of these families, there is an urgent
need for prospective controlled studies. The workshops in
Mallorca have identified several collaborative studies that the
group will focus on to clarify some of the current controversial
issues in the clinical management of FAP.
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ANSWER
From the question on page 672
Features compatible with Crohn’s disease were seen at
colonoscopy, with ‘‘cobblestoning’’, aphthous ulceration and
non-caseating granulomas in the terminal ileum and ascending
colon (fig 1). Behc¸et’s disease was excluded given the absence of
pathergy and genital ulceration in this case.
The clinical presentation and features on skin biopsy suggest
a diagnosis of Crohn’s disease-related, bowel-associated derma-
tosis–arthritis syndrome. Following intravenous hydrocortisone
her dysphagia and arthritis rapidly resolved and she was
commenced on azathioprine.
Bowel-associated dermatosis–arthritis syndrome (also known
as bowel-bypass syndrome) is a rare manifestation of Crohn’s
disease1 3 4 The disorder is characterised by arthralgia, polyar-
thritis and vesiculopustular eruptions on the upper limbs and
trunk.1–4 The skin lesions develop over 24–48 h and usually
resolve spontaneously within 8 days.1 They may be recurrent.
Biopsy of these lesions classically demonstrates a perivascular
and frequently diffuse infiltrate of neutrophils, in the absence of
a leucocytoclastic vasculitis. The disorder was originally
reported following jejeno-ileal bypass surgery for morbid
obesity.2 Subsequently, it has been shown to complicate other
gastrointestinal pathologies such as inflammatory bowel disease
(IBD) and following Billroth 11 gastrectomy.1 It is thought to
form part of the spectrum of neutrophilic dermatoses associated
with IBD, which include pyoderma gangrenosum, pustular
eruption of ulcerative colitis and Sweet’s syndrome. These
varied skin manifestations have overlapping features and may
occur simultaneously.5 Bowel-associated dermatosis–arthritis
syndrome can be distinguished from Sweet’s syndrome by the
morphology of the rash as well as more rapid resolution of
cutaneous lesions, and from pyoderma gangrenosum and
pustular eruption by the upper limb distribution and lack of
skin ulceration and necrosis. The pathogenesis is unclear but
appears to involve circulating immune complexes formed by
antibodies to bacterial peptidoglycan. It usually responds
promptly to antibiotic therapies (tetracycline, sulfamethoxa-
zole/trimethoprim or metronidazole) or corticosteroids.
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Figure 1 Ascending colonic biopsy showing active Crohn’s colitis with
crypt abscesses, mucosal erosion, and non-necrotising granulomatous
inflammation with a Langhans-type giant cell (arrow).
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